Presymptomatic identification of cancers in pregnant women during noninvasive prenatal testing

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 814-819

  Amant, Frédéric ^a   Verheecke, Magali ^a   Wlodarska, Iwona ^a   Dehaspe, Luc ^a   Brady, Paul ^a   Brison, Nathalie ^a   Van Den Bogaert, Kris ^a   Dierickx, Daan ^a   Vandecaveye, Vincent ^a,b   Tousseyn, Thomas ^a   Moerman, Philippe ^a   Vanderstichele, Adriaan ^a   Vergote, Ignace ^a   Neven, Patrick ^a   Berteloot, Patrick ^b   Putseys, Katrien ^c   Danneels, Lode ^d   Vandenberghe, Peter ^a   Legius, Eric ^a   Vermeesch, Joris Robert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Heilig Hart General Hospital   (Belgium)

^d Department of Pathology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TUMOR MARKER;

ASYMPTOMATIC DISEASE; BIOPSY; BLOOD; CASE REPORT; DIFFUSION WEIGHTED IMAGING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HODGKIN DISEASE; HUMAN; LYMPHOMA, FOLLICULAR; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PRENATAL DIAGNOSIS; PROCEDURES; PROGNOSIS; WHOLE BODY IMAGING;

ASYMPTOMATIC DISEASES; BIOMARKERS, TUMOR; BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HODGKIN DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, FOLLICULAR; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PRENATAL DIAGNOSIS; PROGNOSIS; WHOLE BODY IMAGING;

EID: 84943394447     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1883     Document Type: Article

References (15)

1. Bianchi DW, Wilkins-Haug L. Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road? Clin Chem. 2014;60(1):78-87.
2. Lau TK, Jiang FM, Stevenson RJ, et al. Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat Diagn. 2013; 33(6):602-608.
3. Bayindir B, Dehaspe L, Brison N, et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur J Hum Genet. 2015.
4. Heitzer E, Ulz R, Belic J, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5 (4):30.
5. Chan KC, Jiang R Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2013;59(1):211-224.
6. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
7. Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2014;2 (2):e55-e65.
8. Osborne CM, Hardisty E, Devers P, et al. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn. 2013;33(6):609-611.
9. McCullough RM, Almasri EA, Guan X, et al. Non-invasive prenatal chromosomal aneuploidy testing-clinical experience: 100, 000 clinical samples. PLoS One. 2014;9(10):e109173.
10. National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). SEER Cancer Statistics Fact Sheets: Non-Hodgkin Lymphoma. Bethesda, MD: National Cancer Institute; 2015.
11. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
12. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815): 580-587.
13. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;13(3):256-264.
14. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013; 31(20):2532-2539.
15. Han SN, Verheecke M, Vandenbroucke T, Gziri MM, Van Calsteren K, Amant F. Management of gynecological cancers during pregnancy. Curr Oncol Rep. 2014;16(12):415.